Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
povidone-iodine + lidocaine hydrochloride + bupivacaine
- Development stage
- Unknown
- Lead developer
- Asclemed USA
- Modality
- Small Molecules
- Administration
- Epidural, Infiltration, Topical
01
Overview
povidone-iodine + lidocaine hydrochloride + bupivacaine is a marketed combination pharmaceutical product comprising the antiseptic povidone-iodine together with the amide local anesthetics lidocaine hydrochloride and bupivacaine. Marketed by Asclemed USA under the brand name Marlido, the product is used to provide local or regional anesthesia and analgesia while also delivering topical antisepsis at the procedural site. Lidocaine and bupivacaine reduce nerve impulse initiation and conduction primarily by reversibly blocking voltage-gated sodium channels in neuronal membranes, with lidocaine contributing relatively rapid local anesthetic action and bupivacaine contributing longer-duration anesthesia and analgesia; povidone-iodine acts as a broad-spectrum iodophor antiseptic that releases free iodine and kills microorganisms through oxidation and iodination of cellular components.
- Brand names
- MarlidoMarlido 25 KitMarlido25 KitMarlido-25 Kit
- Other names
- povidone-iodine + lidocaine hydrochloride + bupivacaine
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on povidone-iodine + lidocaine hydrochloride + bupivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on povidone-iodine + lidocaine hydrochloride + bupivacaine.